Premium
New drugs on the horizon in bronchogenic carcinoma
Author(s) -
Carter Stephen K.
Publication year - 1972
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197211)30:5<1402::aid-cncr2820300539>3.0.co;2-n
Subject(s) - medicine , lung cancer , bleomycin , cyclophosphamide , bronchogenic carcinoma , drug , clinical trial , chemotherapy , cancer , oncology , pharmacology
The Chemotherapy Program of the National Cancer Institute in its drug development function sponsors for clinical trial a wide range of new antiplastic drugs. All of these drugs are tested in lung cancer which is considered one of the Program's “signal” tumor types. Among the new drugs sponsored for trial, which have shown evidence of activity against lung cancer, are the nitrosoureas of which three are in various stages of clinical evaluation. BCNU has shown activity in 9/83 (11%) while CCNU has shown activity in 11/52 (21%). The newest analogue, Methyl CCNU, is of great interest because of its superior activity against the advanced Lewis lung tumor. Other new agents which have shown some evidence of activity include adriamycin (30/147 = 20%), hexamethylmelamine (42/202 = 21%), and bleomycin (5/62 = 8%). Among the new drugs just completing Phase I evaluation and awaiting trial in lung cancer are: Iphosphamide (NSC 109724) an analogue of cyclophosphamide, ICRF‐159 (NSC 129943), 5‐azacytidine (NSC 102816), and Cis‐platinum (II) Diamminodichloride (NSC 119875).